Welcome to our dedicated page for Aptargroup news (Ticker: ATR), a resource for investors and traders seeking the latest updates and insights on Aptargroup stock.
AptarGroup, Inc. develops drug delivery and consumer-product dosing, dispensing and protection technologies for pharmaceutical, beauty, food, beverage, personal care and home care markets. News about ATR commonly covers operating results across Pharma, Beauty and Closures, demand trends in prescription drug delivery, biologics, injectables, nasal delivery, fragrance dispensing and closure applications.
Company updates also include product introductions such as inverted lidless dispensing closures using SimpliSqueeze® valve technology, Aptar Pharma delivery systems used in clinical-stage nasal therapies, Aptar Digital Health partnerships, dividend declarations, share repurchases and investor presentations.
Aptar (NYSE:ATR) will present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026. Stephan Tanda, President and CEO, will present at 11:15 a.m. Eastern; Vanessa Kanu, EVP and CFO, and Gael Touya, President Aptar Pharma, will also be available.
A live audio webcast and presentation materials will be accessible in the Investors section of the company website at www.aptar.com.
Aptar (NYSE: ATR) announced its Bidose (BDS) Liquid Nasal Spray System is the delivery mechanism for CARDAMYST (etripamil) nasal spray, which received FDA approval for conversion of acute symptomatic PSVT to sinus rhythm in adults on December 17, 2025.
The product pairs two Bidose devices in a protective dual-container with an integrated cap designed to prevent accidental activation and aid portability. Aptar provided device development and regulatory support via its Pharma Services offerings in collaboration with Milestone Pharmaceuticals.
Aptar (NYSE: ATR) was named one of America’s Most Responsible Companies 2026 by Newsweek for the seventh consecutive year, ranking 56 of 600 U.S. companies. The recognition covers ESG performance across Environment, Social and Governance and used 30+ KPIs plus a 26,000-person perception survey. Aptar highlighted investments in renewable energy, landfill-free site certifications, recyclable/refillable product design, and ongoing sustainability reporting.
Aptar (NYSE: ATR) announced on December 1, 2025 that it has acquired Sommaplast, a Brazil-based supplier of oral dosing pharma packaging including closures, droppers, dispensers and dosing cups.
Sommaplast operates a facility in Sao Paulo with a team of over 400 employees and more than 20 years of history. The acquisition expands Aptar's manufacturing footprint in Brazil alongside facilities in Cajamar, Jundiaí, Maringá and Camaçari and is framed as a move to strengthen presence in Latin America and capture growth in Brazil's oral dosing, OTC and nutraceutical markets.
Aptar (NYSE: ATR) announced it will present at the Jefferies Global Healthcare Conference on Wednesday, November 19, 2025. Stephan Tanda, President and CEO, will present at 7:00 a.m. Eastern Standard Time, with Vanessa Kanu, Executive Vice President and CFO, and Gael Touya, President Aptar Pharma, also available. A live audio webcast and presentation materials will be accessible in the Investors section of the company's website at www.aptar.com.
Summary not available.
Aptar Digital Health (ATR) announced that the U.S. FDA granted 510(k) clearance on October 16, 2025 for HeroTracker® Sense, a Bluetooth-enabled Class II connected add-on sensor for pressurized metered-dose inhalers (pMDIs).
HeroTracker Sense is designed for users aged 12 and above, is compatible with commonly prescribed asthma and COPD inhalers including Ventolin HFA and Advair, and integrates with Aptar's Respiratory Disease Management Platform to provide real-time usage tracking, reminders, inhaler technique feedback, and educational resources via a mobile app.
Aptar (NYSE: ATR) was named one of the World’s Top Companies for Women 2025 by Forbes and Statista, marking the company’s fifth consecutive year on the list. Aptar is ranked 72 of 400 companies evaluated from an anonymous survey of over 120,000 women in 36 countries. The ranking is based on employer brand, public opinion and leadership score from surveys conducted over a two-year period.
AptarGroup (NYSE:ATR) has announced a 7% increase in its quarterly cash dividend to $0.48 per share, bringing the annualized dividend to $1.92 per share. The dividend will be paid on November 13, 2025, to stockholders of record as of October 23, 2025.
The company has demonstrated strong financial performance, having returned over $1 billion to shareholders through dividends and share repurchases since 2020. This increase positions Aptar to achieve its 32nd consecutive year of increasing total annual dividend, reflecting the company's sustained growth particularly in its Pharma segment.
AptarGroup (NYSE:ATR), a leader in drug and consumer product dosing, dispensing and protection technologies, will host its 2025 Investor Day on Tuesday, September 9, 2025 from 9:00 a.m. to 12:00 p.m. EDT.
The event will feature presentations by executive management, followed by a Q&A session. In-person attendees will have access to an innovation demonstration and group lunch with management. While in-person attendance is invitation-only, the general public can access the event via webcast by registering online.
Presentation materials will be available on investors.aptar.com on the day of the event.